# Bone health and treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/bone-health-and-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the use of bisphosphonates in the treatment of bone metastases and associated complications, particularly osteonecrosis of the jaw. It explores the mechanisms of action, clinical features, and therapeutic opportunities for bisphosphonates in cancer treatment, with a specific emphasis on prostate and breast cancer. The papers also discuss the role of bisphosphonates in maintaining bone health and preventing skeletal complications in cancer patients. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11221 |
| Works | 297 |

## Topic papers all

Showing 15 of 297.

- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development](https://scholariq.org/papers/cbfa1-a-candidate-gene-for-cleidocranial-dysplasia-syndrome-is-essential-for/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)
- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study](https://scholariq.org/papers/denosumab-versus-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with/)
- [Postmenopausal Osteoporosis](https://scholariq.org/papers/postmenopausal-osteoporosis/)
- [Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research](https://scholariq.org/papers/bisphosphonate-associated-osteonecrosis-of-the-jaw-report-of-a-task-force-of-the/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer/)
- [The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis](https://scholariq.org/papers/the-effects-of-parathyroid-hormone-and-alendronate-alone-or-in-combination-in/)
- [Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research](https://scholariq.org/papers/atypical-subtrochanteric-and-diaphyseal-femoral-fractures-report-of-a-task-force/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term/)
- [Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.](https://scholariq.org/papers/origin-of-osteoclasts-mature-monocytes-and-macrophages-are-capable-of/)

## Topic primary papers

Showing 15 of 70.

- [Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study](https://scholariq.org/papers/denosumab-versus-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with/)
- [Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research](https://scholariq.org/papers/bisphosphonate-associated-osteonecrosis-of-the-jaw-report-of-a-task-force-of-the/)
- [Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them](https://scholariq.org/papers/adverse-effects-of-androgen-deprivation-therapy-and-strategies-to-mitigate-them/)
- [Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer](https://scholariq.org/papers/randomized-controlled-trial-of-zoledronic-acid-to-prevent-bone-loss-in-men/)
- [Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure](https://scholariq.org/papers/prevalence-of-osteonecrosis-of-the-jaw-in-patients-with-oral-bisphosphonate/)
- [Load-Bearing Mode of the Knee Joint](https://scholariq.org/papers/load-bearing-mode-of-the-knee-joint/)
- [Removal of Osteoclast Bone Resorption Products by Transcytosis](https://scholariq.org/papers/removal-of-osteoclast-bone-resorption-products-by-transcytosis/)
- [Toxic acute tubular necrosis following treatment with zoledronate (Zometa)](https://scholariq.org/papers/toxic-acute-tubular-necrosis-following-treatment-with-zoledronate-zometa/)
- [A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide \[Recombinant Human Parathyroid Hormone (1–34)\] with Alendronate in Postmenopausal Women with Osteoporosis](https://scholariq.org/papers/a-randomized-double-blind-trial-to-compare-the-efficacy-of-teriparatide/)
- [Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study](https://scholariq.org/papers/overall-survival-improvement-in-patients-with-lung-cancer-and-bone-metastases/)
- [Further Insight into Mechanism of Action of Clodronate: Inhibition of Mitochondrial ADP/ATP Translocase by a Nonhydrolyzable, Adenine-Containing Metabolite](https://scholariq.org/papers/further-insight-into-mechanism-of-action-of-clodronate-inhibition-of/)
- [Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts](https://scholariq.org/papers/bisphosphonates-pamidronate-and-zoledronic-acid-stimulate-osteoprotegerin/)
- [Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw](https://scholariq.org/papers/antiresorptive-agent-related-osteonecrosis-of-the-jaw-position-paper-2017-of-the/)
- [Management of the adverse effects associated with intravenous bisphosphonates](https://scholariq.org/papers/management-of-the-adverse-effects-associated-with-intravenous-bisphosphonates/)
- [A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonates](https://scholariq.org/papers/a-new-endogenous-atp-analog-apppi-inhibits-the-mitochondrial-adenine-nucleotide/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.